On Tuesday 18 November 2025, the Federal Agency for Medicines and Health Products (FAMHP) once again appeared before the House of Representatives regarding the sperm donor case involving a sperm donor who carried a TP53 gene mutation and the failure to comply with the legal limit of six women per donor.
Hugues Malonne (Chief Executive Officer), Ethel Mertens (Director-General of the DG Inspection) and Erik Everaert (Director-General of the DG POST authorisation) took part in an exchange of views on the FAMHP inspection reports and the Federal Internal Audit report during the Commission on Health and Equal Opportunity meeting on 18 November 2025.
During this session, the representatives of the FAMHP answered the 192 parliamentary questions received following the committee meeting of 4 November 2025, grouping them by theme and leaving it to the Minister of Health to respond to questions that concerned him directly. The Federal Internal Audit auditors then answered the questions addressed to them.
The recording of the session is available on the website of the House of Representatives.
Contact
For further information, please send an email to icm@afmps-fagg.be.